Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma
NCT02639182Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- May 2016
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ags-16m8f in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Progression Free Survival up to 53 months. Started May 2016; status: completed.
02
Drugs
ags-16m8f
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02639182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639182.